|
Egalet a/s is a specialty pharma company focusing on pain management. Egalet has several opioid compounds in development and the most advanced program (Egalet Morphine EG-P066) is in clinical phase II.
Egalet holds various proprietary drug delivery technologies within formulation and development that enables it to develop controlled release products with true drug abuse resistance and non-alcohol dose dumping.
The Egalet® tablet is one in a series of controlled release products developed by Egalet a/s. The Egalet® technology works by incorporating the active ingredient into a polymeric matrix that is eroded by body fluids at a constant rate. The tablet is made by way of injection moulding techniques involving only a few steps. The Egalet® technique breaks new ground because it can be used for virtually any type of medicine and because it provides controlled release with unusual precision and reliability.
Parvulet™ delivery platform is facilitating dispensing of oral doses especially to the pediatric and geriatric patient segments, and where necessary large doses.
Egalet is funded by strong international and Scandinavian Venture Funds.
|
